Focal Therapeutics→Hologic
Acquisition · Cash · HOLX · announced Sep 26, 2018
Announced
Sep 26, 2018
Closed
Oct 1, 2018
Economics
Cash()
Pre-deal · pre-deal mark: 2018, year precision · Hologic 8-K filing, SEC EDGAR — Focal Therapeutics acquisition
~$125M cash (SEC filing shows $120.1M final purchase price)
Target
Focal Therapeutics
Breast Health · Clinical / therapeutic
HQ Aliso Viejo, CA · Founded 2004
BioZorb implantable 3D marker for breast conserving surgery (lumpectomy) — marks tumor excision site for monitoring and treatment planning
- Hologic investor relations press release (Sep 26, 2018)
- SEC EDGAR — Hologic 10-K FY2019 (purchase price $120.1M)
Acquirer
Hologic (HOLX)
Breast Health
HQ Marlborough, MA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
BioZorb 3D marker strengthens breast conserving surgery franchise — complements Faxitron biopsy imaging in rapidly growing lumpectomy market
Evidence ladder
Secondary (press / IR)
Hologic investor relations press release (Sep 26, 2018)
Primary (regulatory / filing)
SEC 10-K FY2019
SEC EDGAR filings (ticker locator)
Limitations
- ~$125M cash (SEC filing shows $120.1M final purchase price)
- Pre-deal valuation sourced from: Hologic 8-K filing, SEC EDGAR — Focal Therapeutics acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Breast Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Faxitron Bioptics | Hologic | Jul 31, 2018 | same acquirer | |
| SuperSonic Imagine | Hologic | Jun 21, 2019 | same acquirer | |
| Biotheranostics | Hologic | Jan 5, 2021 | same acquirer | |
| Sividon Diagnostics | Myriad Genetics | May 31, 2016 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Immunomedics | Gilead Sciences | Sep 13, 2020 |
Other verified deals by Hologic
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Gynesonics | Hologic | Sep 15, 2024 | Gynecological Surgery | |
| Endomagnetics | Hologic | May 20, 2024 | Breast Health | |
| Bolder Surgical | Hologic | Oct 14, 2021 | Gynecological Surgery | |
| Acessa Health | Hologic | Aug 25, 2020 | Gynecological Surgery | |
| Gen-Probe | Hologic | Apr 30, 2012 | Diagnostics |
Patient empowerment context
Empowerment context — Focal Therapeutics
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- No survivorship care plan after active treatment54%cited HLTH 2022
Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Flatiron Health
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.